Impact of the MTHFR C677T polymorphism on risk of Wilms tumor: Case-control study

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 4, 2009, Pages 256-258

  Ferrara, Mara ^a   Capozzi, Laura ^a   Russo, Rosa ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Folate; MTHFR C677T genotype; Wilms tumor

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; FOLATE METABOLISM; GENOTYPE; HUMAN; ITALY; MALE; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; KIDNEY TUMOR; RISK FACTOR;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; ITALY; KIDNEY NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; RISK FACTORS; WILMS TUMOR;

EID: 65349152127     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318196a40c     Document Type: Article

References (24)

1. Stern LL, Mason JB, Selhub J, et al. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methhylenetetrahydrofo-late reductase gene. Cancer Epidemiol. 2000;9:849-853.
2. Botto LD, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151:862-877.
3. Kirke PN, Mills JL, Molloy AM, et al. Impact of MTHFR C677T polymorphism on risk of neural tube defects: case control study. BMJ. 2004;328:1535-1536.
4. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahy-drofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996;56:4862-4864.
5. Gemmati D, Ongaro A, Scapoli GL et al. Common gene polymorphism in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukaemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol. 2004; 13:787-793.
6. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene-tetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
7. Scott JRH, Stiller CA, Walker L, et al. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J. Med Genet. 2006;43:705-715.
8. Moreno García M, Sánchez del Pozo J, Fernández Martínez FJ, et al. WAGR syndrome: a case report. An Esp Pediatr. 1998;49:381-387.
9. Fischbach BV, Trout KL, Lewis J, et al. WAGR syndrome: a clinical review of 54 cases. Pediatrics. 2005;116:984-988.
10. Mahale A, Poornima V, Shrestha M. WAGR syndrome: a case report. Nepal Med Coll J. 2007;9:138-140.
11. van Heyningen V, Hoovers JM, de Kraker J, et al. Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion. J Med Genet. 2007;44:787-790. Epub July 14, 2007.
12. Chiang PW, Aliaga S, Travers S, et al. Case report: WT1 exon 6 truncation mutation and ambiguous genitalia in a patient with Denys-Drash syndrome. Curr Opin Pediatr. 2008;20: 103-106.
13. Weksberg R, Nishikawa J, Caluseriu O, et al. Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet. 2001;10:2989-3000.
14. Gaston V, Le Bouc Y, Soupre V, et al. Analysis of the methylation status of the KCNQ1OT and H19 genes in leukocyte DNA for the diagnosis and prognosis of Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2001;9:409-418.
15. Bliek J, Maas SM, Ruijter JM, et al. Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypo-methylation in familial cases of BWS. Hum Mol Genet. 2001; 10:467-476.
16. Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr. 2004;145: 796-799.
17. Reeve AE, Eccles MR, Wilkins RJ, et al. Expression of insulinlike growth factor-II transcripts in Wilms' tumour. Nature. 1985;317:258-260.
18. Scott J, Cowell J, Robertson ME, et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature. 1985;317:260-262.
19. Yi P, Pogribny IP, James SJ. Multiplex PCR for simultaneous detection of 677 C→T and 1298 A→C polymorphism in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett. 2002;181:209-213.
20. Ehrlich M, Jiang G, Fiala E, et al. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene. 2002; 21:6694-6702.
21. Costello JF, Plass C. Methylation matters. Med Genet. 2001; 38:285-303.
22. Hunin GR, Nass CC, Kramer S, et al. Parental occupation and Wilms tumor. Results of a case-control study. Cancer Res. 1989;49:725-729.
23. Olshan AF, Breslow NE, Falletta JM, et al. Risk factors for Wilms tumor: report from the National Wilms Tumor Study. Cancer. 1993;72:938-944.
24. Zack M, Cannon S, Loyd D, et al. Cancer in children of parents exposed to hydrocarbon-related industries and occupations. Am J Epidemiol. 1980;3:329-336.